Skip to main content
PMC home page
Heart logoLink to Heart
. 1999 Nov;82(5):570–574. doi: 10.1136/hrt.82.5.570

Use of antithrombotic measures for stroke prevention in atrial fibrillation

I Perez 1, A Melbourn 1, L Kalra 1
PMCID: PMC1760775  PMID: 10525511

Abstract

OBJECTIVE—To evaluate appropriateness of antithrombotic use to prevent stroke in atrial fibrillation.
DESIGN, PATIENTS—344 patients with atrial fibrillation, stratified by age, were assessed clinically for contraindications to anticoagulation and stroke risk. The use of warfarin and aspirin was compared with recommendations for anticoagulation derived from pooled clinical trial data.
RESULTS—Low risk of stroke was seen in 47 (14%) patients, moderate risk in 213 (62%), and high risk in 84 (24%) patients included in the sample (mean (SD) age 68.4 (17.2) years, 42% men). The proportion of patients requiring anticoagulation varied from 258/344 (75%) to 72/344 (21%) depending upon criteria used, of whom 86/258 (33%) and 36/72 (50%) were receiving warfarin, respectively. Warfarin or aspirin were not being used in 124/297 (42%) patients with moderate to high risk, whereas anticoagulation was being undertaken in 13/47 (27%) patients at low risk of stroke. Antithrombotic use (warfarin or aspirin) was significantly less common in patients over 75 years of age, regardless of absence of contraindications and eligibility according to various criteria (p < 0.001).
CONCLUSIONS—A clear need for anticoagulation using clinical criteria existed in about 25% of patients in atrial fibrillation presenting to medical clinics who were at high risk of stroke. Of these, only 50% of eligible patients were being anticoagulated. Appropriate anticoagulation needs to be based on risk assessment rather than age. Consensus is therefore needed on appropriate antithrombotic use in clinical practice.


Keywords: stroke prevention; atrial fibrillation; warfarin; aspirin; antithrombotics

Full Text

The Full Text of this article is available as a PDF (74.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albers G. W., Yim J. M., Belew K. M., Bittar N., Hattemer C. R., Phillips B. G., Kemp S., Hall E. A., Morton D. J., Vlasses P. H. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med. 1996 Nov 11;156(20):2311–2316. [PubMed] [Google Scholar]
  2. Betteridge D. J., Dodson P. M., Durrington P. N., Hughes E. A., Laker M. F., Nicholls D. P., Rees J. A., Seymour C. A., Thompson G. R., Winder A. F. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J. 1993 May;69(811):359–369. doi: 10.1136/pgmj.69.811.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brass L. M., Krumholz H. M., Scinto J. M., Radford M. Warfarin use among patients with atrial fibrillation. Stroke. 1997 Dec;28(12):2382–2389. doi: 10.1161/01.str.28.12.2382. [DOI] [PubMed] [Google Scholar]
  4. Feinberg W. M. Anticoagulation for prevention of stroke. Neurology. 1998 Sep;51(3 Suppl 3):S20–S22. doi: 10.1212/wnl.51.3_suppl_3.s20. [DOI] [PubMed] [Google Scholar]
  5. Glasziou P. P., Irwig L. M. An evidence based approach to individualising treatment. BMJ. 1995 Nov 18;311(7016):1356–1359. doi: 10.1136/bmj.311.7016.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Goldstein L. B., Farmer A., Matchar D. B. Primary care physician-reported secondary and tertiary stroke prevention practices. A comparison between the United States and the United Kingdom. Stroke. 1997 Apr;28(4):746–751. doi: 10.1161/01.str.28.4.746. [DOI] [PubMed] [Google Scholar]
  7. Gottlieb L. K., Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 1994 Sep 12;154(17):1945–1953. doi: 10.1001/archinte.154.17.1945. [DOI] [PubMed] [Google Scholar]
  8. Green C. J., Hadorn D. C., Bassett K., Kazanjian A. Anticoagulation in chronic nonvalvular atrial fibrillation: a critical appraisal and meta-analysis. Can J Cardiol. 1997 Sep;13(9):811–815. [PubMed] [Google Scholar]
  9. Guidelines for medical treatment for stroke prevention. American College of Physicians. Ann Intern Med. 1994 Jul 1;121(1):54–55. doi: 10.7326/0003-4819-121-1-199407010-00009. [DOI] [PubMed] [Google Scholar]
  10. Gustafsson C., Asplund K., Britton M., Norrving B., Olsson B., Marké L. A. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ. 1992 Dec 12;305(6867):1457–1460. doi: 10.1136/bmj.305.6867.1457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kalra L., Perez I., Melbourn A. Stroke risk management: changes in mainstream practice. Stroke. 1998 Jan;29(1):53–57. doi: 10.1161/01.str.29.1.53. [DOI] [PubMed] [Google Scholar]
  12. Koefoed B. G., Gulløv A. L., Petersen P. Prevention of thromboembolic events in atrial fibrillation. Thromb Haemost. 1997 Jul;78(1):377–381. [PubMed] [Google Scholar]
  13. Laupacis A., Albers G., Dalen J., Dunn M., Feinberg W., Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest. 1995 Oct;108(4 Suppl):352S–359S. doi: 10.1378/chest.108.4_supplement.352s. [DOI] [PubMed] [Google Scholar]
  14. Lip G. Y., Lowe G. D. ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. BMJ. 1996 Jan 6;312(7022):45–49. doi: 10.1136/bmj.312.7022.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lip G. Y., Lowe G. D. ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. BMJ. 1996 Jan 6;312(7022):45–49. doi: 10.1136/bmj.312.7022.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McCrory D. C., Matchar D. B., Samsa G., Sanders L. L., Pritchett E. L. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995 Feb 13;155(3):277–281. [PubMed] [Google Scholar]
  17. O'Mahony P. G., Dobson R., Rodgers H., James O. F., Thomson R. G. Validation of a population screening questionnaire to assess prevalence of stroke. Stroke. 1995 Aug;26(8):1334–1337. doi: 10.1161/01.str.26.8.1334. [DOI] [PubMed] [Google Scholar]
  18. Sever P., Beevers G., Bulpitt C., Lever A., Ramsay L., Reid J., Swales J. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ. 1993 Apr 10;306(6883):983–987. doi: 10.1136/bmj.306.6883.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sudlow C. M., Rodgers H., Kenny R. A., Thomson R. G. Service provision and use of anticoagulants in atrial fibrillation. BMJ. 1995 Aug 26;311(7004):558–560. doi: 10.1136/bmj.311.7004.558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sudlow M., Thomson R., Thwaites B., Rodgers H., Kenny R. A. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet. 1998 Oct 10;352(9135):1167–1171. doi: 10.1016/S0140-6736(98)01401-9. [DOI] [PubMed] [Google Scholar]
  21. Thomson R., McElroy H., Sudlow M. Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment. BMJ. 1998 Feb 14;316(7130):509–513. doi: 10.1136/bmj.316.7130.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Whittle J., Wickenheiser L., Venditti L. N. Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med. 1997 Feb 24;157(4):441–445. [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES